416 related articles for article (PubMed ID: 34212214)
1. Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD.
Gupta M; Krishan P; Kaur A; Arora S; Trehanpati N; Singh TG; Bedi O
Inflamm Res; 2021 Jul; 70(7):765-776. PubMed ID: 34212214
[TBL] [Abstract][Full Text] [Related]
2. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies.
Ebrahimzadeh Leylabadlo H; Ghotaslou R; Samadi Kafil H; Feizabadi MM; Moaddab SY; Farajnia S; Sheykhsaran E; Sanaie S; Shanehbandi D; Bannazadeh Baghi H
Eur J Clin Microbiol Infect Dis; 2020 Apr; 39(4):613-627. PubMed ID: 31828683
[TBL] [Abstract][Full Text] [Related]
3. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.
Han R; Ma J; Li H
Front Med; 2018 Dec; 12(6):645-657. PubMed ID: 30178233
[TBL] [Abstract][Full Text] [Related]
5. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
6. Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial.
Xue L; Deng Z; Luo W; He X; Chen Y
Front Cell Infect Microbiol; 2022; 12():759306. PubMed ID: 35860380
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view.
Chen HT; Huang HL; Li YQ; Xu HM; Zhou YJ
World J Gastroenterol; 2020 Apr; 26(16):1901-1911. PubMed ID: 32390701
[TBL] [Abstract][Full Text] [Related]
8. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review.
Chen YH; Wu WK; Wu MS
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825440
[TBL] [Abstract][Full Text] [Related]
9. Fighting Fatty Liver Diseases with Nutritional Interventions, Probiotics, Symbiotics, and Fecal Microbiota Transplantation (FMT).
Nobili V; Mosca A; Alterio T; Cardile S; Putignani L
Adv Exp Med Biol; 2019; 1125():85-100. PubMed ID: 30578461
[TBL] [Abstract][Full Text] [Related]
10. Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response.
Delaune V; Orci LA; Lacotte S; Peloso A; Schrenzel J; Lazarevic V; Toso C
Expert Opin Biol Ther; 2018 Oct; 18(10):1061-1071. PubMed ID: 30173562
[TBL] [Abstract][Full Text] [Related]
11. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H
J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054
[TBL] [Abstract][Full Text] [Related]
12. Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies.
Jayachandran M; Qu S
Rev Endocr Metab Disord; 2023 Dec; 24(6):1189-1204. PubMed ID: 37840104
[TBL] [Abstract][Full Text] [Related]
13. Faecal Microbiota Transplantation, Paving the Way to Treat Non-Alcoholic Fatty Liver Disease.
Del Barrio M; Lavín L; Santos-Laso Á; Arias-Loste MT; Odriozola A; Rodriguez-Duque JC; Rivas C; Iruzubieta P; Crespo J
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047094
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?
Aron-Wisnewsky J; Warmbrunn MV; Nieuwdorp M; Clément K
Gastroenterology; 2020 May; 158(7):1881-1898. PubMed ID: 32044317
[TBL] [Abstract][Full Text] [Related]
15. Gut microbiome and non-alcoholic fatty liver disease.
Purohit A; Alam MJ; Kandiyal B; Shalimar ; Das B; Banerjee SK
Prog Mol Biol Transl Sci; 2022; 191(1):187-206. PubMed ID: 36270678
[TBL] [Abstract][Full Text] [Related]
16. Gut Microbiota as a Therapeutic Target for Metabolic Disorders.
Okubo H; Nakatsu Y; Kushiyama A; Yamamotoya T; Matsunaga Y; Inoue MK; Fujishiro M; Sakoda H; Ohno H; Yoneda M; Ono H; Asano T
Curr Med Chem; 2018; 25(9):984-1001. PubMed ID: 28990516
[TBL] [Abstract][Full Text] [Related]
17. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota.
Zhou D; Pan Q; Shen F; Cao HX; Ding WJ; Chen YW; Fan JG
Sci Rep; 2017 May; 7(1):1529. PubMed ID: 28484247
[TBL] [Abstract][Full Text] [Related]
18. Fecal Microbiota Transplantation in NAFLD Treatment.
Abenavoli L; Maurizi V; Rinninella E; Tack J; Di Berardino A; Santori P; Rasetti C; Procopio AC; Boccuto L; Scarpellini E
Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363516
[No Abstract] [Full Text] [Related]
19. Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates.
Khan A; Ding Z; Ishaq M; Bacha AS; Khan I; Hanif A; Li W; Guo X
Int J Biol Sci; 2021; 17(3):818-833. PubMed ID: 33767591
[TBL] [Abstract][Full Text] [Related]
20. Functional Interactions between Gut Microbiota Transplantation, Quercetin, and High-Fat Diet Determine Non-Alcoholic Fatty Liver Disease Development in Germ-Free Mice.
Porras D; Nistal E; Martínez-Flórez S; Olcoz JL; Jover R; Jorquera F; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Mol Nutr Food Res; 2019 Apr; 63(8):e1800930. PubMed ID: 30680920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]